Every expiry date printed on a carton comes from a stability study — not from an estimate, but from real samples sitting in controlled chambers for years while a laboratory tests them on a schedule.
Stability studies answer three questions: how long the product stays within specification, what storage conditions it needs, and whether the pack protects it. A product with a valid shelf life in Europe may have no data supporting the same claim in Indonesia, because those markets require different storage conditions.
This guide covers the ICH framework, the temperature and humidity combinations used, accelerated versus real-time data, and what to request from a supplier before committing to a registration.
Quick answer: Stability studies are controlled tests that measure how a drug substance or drug product changes over time under defined temperature, humidity, and light conditions. They establish the shelf life or retest period, the labelled storage statement, and whether the proposed container closure system gives adequate protection.
Table of Contents
- What Stability Studies Actually Establish
- The ICH Guidelines That Govern Stability Studies
- ICH Climatic Zones and Why Zone IVb Matters for Exports
- Long-Term, Intermediate and Accelerated Conditions
- Why Accelerated Data Alone Only Supports a Provisional Shelf Life
- Significant Change Criteria
- Stress Testing and Forced Degradation
- What Gets Tested at Each Time Point
- Bracketing and Matrixing: Reducing the Sample Load
- Photostability Testing Under ICH Q1B
- In-Use and Reconstituted Product Stability
- API Retest Date vs Finished Product Expiry Date
- Ongoing Stability Programmes and Annual Commitment Batches
- How Stability Data Supports a Registration Dossier
- What a Buyer Should Request From a Supplier
- Expert Tips
- Common Mistakes
- Frequently Asked Questions
What Stability Studies Actually Establish
The first output is shelf life. For a finished dosage form this becomes the expiry date, beyond which the manufacturer no longer guarantees the product meets specification.
The second is the label storage statement. “Store below 25°C”, “Store below 30°C, protect from light”, “Store in a refrigerator (2°C to 8°C)” — each is a conclusion drawn from data, not a precaution added for comfort.
The third is packaging suitability. Studies run in the exact container closure system proposed for sale, so a blister that lets moisture through shows up as rising water content and falling assay. See pharmaceutical packaging standards.
A fourth is less obvious. The data shows which degradation products form and when, driving the limits that appear on every certificate of analysis.
The ICH Guidelines That Govern Stability Studies
ICH Q1A(R2), Stability Testing of New Drug Substances and Products, is the core document. It sets the study design, storage conditions, minimum number of batches, and testing frequencies that most authorities expect.
Companion guidelines sit around it. Q1B covers photostability, Q1C new dosage forms of an approved product, and Q1D bracketing and matrixing designs.
Q1E, Evaluation for Stability Data, decides how far you can extrapolate. It sets out the approach for judging whether a proposed shelf life is justified by the data so far. Q1F once covered zone III and IV packages but was withdrawn in 2006, leaving hot-climate requirements to WHO guidance and national authorities.
ICH Climatic Zones and Why Zone IVb Matters for Exports
The world is divided into climatic zones based on long-term temperature and humidity. Each zone has a derived storage condition that stability testing is expected to reflect.
| Climatic zone | Description | Typical regions | Long-term storage condition |
|---|---|---|---|
| Zone I | Temperate | Northern Europe, Canada, Russia | 21°C / 45% RH |
| Zone II | Subtropical, Mediterranean | Southern Europe, USA, Japan | 25°C / 60% RH |
| Zone III | Hot and dry | Egypt, parts of the Middle East | 30°C / 35% RH |
| Zone IVa | Hot and humid | Much of Africa, parts of South Asia | 30°C / 65% RH |
| Zone IVb | Hot and very humid | Brazil, Singapore, Indonesia, the Philippines, several ASEAN and Gulf markets | 30°C / 75% RH |
Zone IVb is where exports get complicated. A dossier built on 25°C/60% RH data satisfies Europe and the United States but will not support registration in a market demanding 30°C/75% RH long-term data.
That data cannot be generated retrospectively. Twenty-four months of zone IVb data takes twenty-four months, so an ASEAN or Gulf filing is planned years ahead.
Many manufacturers now run 30°C/65% RH as their default long-term condition, covering zones II, III and IVa in one study. Zone IVb still needs its own chamber. Confirm your destination’s zone early — see pharmaceutical regulatory authorities around the world.
Long-Term, Intermediate and Accelerated Conditions
Three condition types run in parallel for a general-case product stored at room temperature.
| Study type | Standard condition | Minimum duration at submission | Purpose | What it supports |
|---|---|---|---|---|
| Long-term (real-time) | 25°C ± 2°C / 60% RH ± 5% RH, or 30°C ± 2°C / 65% RH ± 5% RH | 12 months | Measures actual behaviour under labelled storage | The approved shelf life and the storage statement |
| Intermediate | 30°C ± 2°C / 65% RH ± 5% RH | 6 months | Bridges the gap when accelerated data shows significant change | Continued reliance on long-term data when accelerated fails |
| Accelerated | 40°C ± 2°C / 75% RH ± 5% RH | 6 months | Stresses the product to expose degradation pathways and short excursions | Provisional shelf life, extrapolation support, shipping excursion assessment |
Long-term testing runs every three months through the first year, every six months through the second, then annually for the rest of the proposed shelf life.
Accelerated studies use a minimum of three time points including initial and final, typically 0, 3 and 6 months. Intermediate studies use a minimum of four: 0, 6, 9 and 12 months.
Refrigerated products use a different pair — long term at 5°C ± 3°C, accelerated at 25°C ± 2°C / 60% RH ± 5% RH. Frozen products sit at −20°C ± 5°C.
Why Accelerated Data Alone Only Supports a Provisional Shelf Life
Accelerated testing rests on a reasonable assumption: reactions speed up at higher temperature, so six months at 40°C/75% RH previews what may happen over two years at room temperature.
The assumption holds for some degradation pathways and breaks for others. Polymorphic conversion, crystallisation in a suspension, or a coating defect may only appear at real-time conditions, or may appear at 40°C purely as an artefact of heat.
So accelerated data alone justifies only a provisional shelf life, granted on condition that real-time data follows as it accumulates. Regulators treat it as a prediction awaiting confirmation.
Q1E allows limited extrapolation where long-term data shows little change and little variability and accelerated data shows no significant change. The extension is capped, and the real-time study continues.
Significant Change Criteria
“Significant change” is a defined trigger, not a judgement call. If it occurs at the accelerated condition, intermediate testing becomes necessary and the shelf life claim rests on real-time data.
For a drug product it means any of the following:
- A 5% change in assay from the initial value, or failure to meet potency criteria where biological or immunological methods are used
- Any degradation product exceeding its acceptance criterion
- Failure to meet acceptance criteria for appearance, physical attributes, or functionality, such as colour, phase separation, resuspendability, caking, hardness, or dose delivery per actuation
- Failure to meet the acceptance criterion for pH
- Failure to meet dissolution acceptance criteria for 12 dosage units
Some physical changes are expected at 40°C and are not automatically disqualifying — a softened suppository or a melted cream base being the standard examples.
For a drug substance the definition is simpler: failure to meet its specification.
Stress Testing and Forced Degradation
Stress testing sits outside the formal stability study. It is deliberately harsh, usually run on a single batch, and asks how the molecule breaks down rather than how long it lasts.
Typical conditions include temperature in increments above the accelerated condition, high humidity, acid and base hydrolysis, oxidation, and light. Each is applied until meaningful degradation appears without destroying the sample.
The output is a set of degradation products, and that set is what makes a method stability-indicating — able to separate and quantify the active ingredient in the presence of everything it degrades into.
What Gets Tested at Each Time Point
Stability testing is not a repeat of full release testing. It focuses on attributes susceptible to change during storage.
The usual set covers appearance, assay, related substances, water content, and the performance test — dissolution for solid orals, disintegration where applicable. pH is added for liquids and semi-solids.
Product-specific tests follow the dosage form: hardness and friability for uncoated tablets; particulate matter, clarity and container closure integrity for injectables; preservative content for multi-dose liquids. Microbiological and sterility testing usually runs at reduced frequency, often annually and at end of shelf life.
Bracketing and Matrixing: Reducing the Sample Load
A product with four strengths in three pack sizes gives twelve combinations. Testing every one at every interval is often unnecessary, so ICH Q1D permits two reduced designs.
Bracketing tests only the extremes — lowest and highest strength, smallest and largest container — on the reasoning that intermediate combinations are represented. It applies where strengths are compositionally proportional and the container type is identical.
Matrixing tests a defined subset at each time point, rotating which combinations are pulled. All are still tested, just not at every interval, and the initial and final points are always tested in full.
Photostability Testing Under ICH Q1B
Light causes degradation independently of heat and moisture, so it gets its own study. Q1B splits the work into forced degradation testing and confirmatory testing.
The exposure standard has two parts: overall illumination of not less than 1.2 million lux hours, plus integrated near-ultraviolet energy of not less than 200 watt hours per square metre. Two lamp options are permitted — a D65/ID65 source, or cool white fluorescent combined with a near-UV lamp.
Testing proceeds in stages: exposed material first, then the immediate pack, then the marketing pack if needed, with a dark control alongside to separate light effects from heat. The result drives the label — “protect from light”, amber glass, or a carton overwrap are photostability conclusions.
In-Use and Reconstituted Product Stability
Shelf life assumes an unopened container. Once a multi-dose product is opened the conditions change, and a separate in-use shelf life applies.
In-use studies cover oral solutions, eye drops, multi-dose injections, and insulin pens. The container is opened and dosed on a realistic schedule, then tested for assay, preservative content, microbiological quality, and appearance. This gives the “use within 14 days of opening” statement.
Reconstituted product stability applies to dry powders such as antibiotic suspensions and lyophilised injections. Testing runs from reconstitution over the proposed in-use period, usually at both room temperature and refrigerated conditions.
API Retest Date vs Finished Product Expiry Date
This distinction confuses first-time importers, and it changes what you can do with material in your warehouse.
A finished dosage form carries an expiry date. After that date it must not be used or supplied. No testing revives it.
An API usually carries a retest date instead. When that date is reached the material is sampled and retested against its specification. If it passes, it can go into manufacture and a new retest date is assigned.
Retest dating suits drug substances that degrade slowly. Less stable APIs get an expiry date instead — see API vs finished dosage form.
Ongoing Stability Programmes and Annual Commitment Batches
Approval is not the end of stability work. GMP requires a continuing programme monitoring marketed product across its labelled shelf life.
The usual commitment is at least one batch per year, per product, per strength, per primary packaging type. If no batch was made that year, it is documented rather than skipped silently.
These annual commitment batches are the first place a problem surfaces after a change — new excipient supplier, modified blister film, different site. An out-of-trend result triggers investigation and, in serious cases, recall.
Auditors look closely here. It is one of the clearest signs of whether a site’s quality system actually operates — see pharmaceutical quality control vs quality assurance.
How Stability Data Supports a Registration Dossier
In the CTD, stability sits in Module 3 — section 3.2.S.7 for the drug substance, 3.2.P.8 for the drug product. Each holds a summary, a post-approval commitment, and the data tables.
Registration normally requires at least three primary batches of both substance and product. For the drug product, at least two should be pilot scale, with the third permitted to be smaller if justified.
Batches must use the same process, specification, and container closure system proposed for marketing. Data generated on a different pack does not transfer.
What a Buyer Should Request From a Supplier
Ask for the full stability report, not a summary sheet. A one-page statement saying “shelf life 36 months” tells you nothing verifiable.
It should identify batch numbers, manufacturing dates, batch sizes, storage conditions with tolerances, the container closure system, and the analytical methods.
Request the data tables at every time point. You want the trend, not the final figure. Related substances creeping upward over 24 months is a different product from one that stays flat.
Confirm the zone. For a zone IVb market, ask whether 30°C/75% RH long-term data exists and how many months are complete — part of the wider check in choosing an API supplier.
Expert Tips
- Ask when the study started, not just how long the shelf life is. A 36-month claim backed by 18 months of real-time data is an extrapolation. Know which position you are in before filing.
- Match the chamber condition to the destination before the first batch goes in. Starting at 25°C/60% RH when your targets are zone IVb wastes years. Running 30°C/65% RH covers zones II, III and IVa in one study.
- Get the method validation report, not just the method. Forced degradation chromatograms showing peak separation are the evidence it works. Without them the method may not be seeing the degradants.
- Check that the pack on stability is the pack you will receive. Suppliers sometimes run stability in the largest pack and ship a smaller one, or change blister film after approval. Both alter the moisture barrier.
- Treat significant change at accelerated as information, not a red flag on its own. Many stable products change at 40°C/75% RH. What matters is whether intermediate and long-term data hold.
- Ask for in-use data before registering a multi-dose product. Several markets reject the dossier without it.
Common Mistakes
- Accepting accelerated data as proof of shelf life. Six months at 40°C/75% RH supports a provisional claim only, and registration stalls until real-time data catches up.
- Assuming one dossier covers every export market. A file built on zone II data gets queried or rejected in zone IVb markets, and the fix takes years.
- Ignoring the storage statement when planning logistics. A product labelled “store below 25°C” crossing a Gulf port in summer has no data covering what happens next — see temperature-controlled pharmaceutical logistics.
- Treating a retest date as an expiry date, or the reverse. Discarding usable API at its retest date wastes money. Using an FDF past expiry is a regulatory breach.
- Not checking whether stability was run in the marketed pack. Data from a glass bottle does not support a blister, and an assessor spots the mismatch immediately.
- Overlooking photostability for clear or translucent packs. If the pack changed after approval with no photostability bridge, the label claim is unsupported.
Frequently Asked Questions
What are stability studies in pharmaceuticals?
Stability studies are controlled tests measuring how a drug substance or finished product changes under defined temperature, humidity, and light conditions. Samples sit in calibrated chambers and are tested at set intervals for assay, degradation products, appearance, and performance attributes such as dissolution. The results establish the shelf life or retest period, the storage statement on the label, and whether the container closure system protects the product adequately.
What does ICH Q1A(R2) cover?
ICH Q1A(R2) is the core stability guideline, titled Stability Testing of New Drug Substances and Products. It defines the storage conditions, the minimum number of batches, the testing frequency at each condition, what significant change means, and how stress testing is approached. Q1B covers photostability, Q1C new dosage forms, Q1D bracketing and matrixing, and Q1E evaluation of the resulting data.
What is the difference between accelerated and real-time stability testing?
Accelerated testing stores samples at 40°C ± 2°C / 75% RH ± 5% RH for six months to speed up degradation and expose failure pathways early. Real-time testing stores samples at the labelled condition, commonly 25°C/60% RH or 30°C/65% RH, for the full shelf life. Accelerated data supports a provisional shelf life only, because some physical changes never appear at elevated temperature.
Which ICH climatic zone applies to hot and humid markets?
Zone IVb covers hot and very humid climates and uses a long-term storage condition of 30°C / 75% RH. It applies to markets including Brazil, Singapore, Indonesia, the Philippines, and several ASEAN and Gulf countries. Zone IVa, at 30°C / 65% RH, covers much of Africa and South Asia. A dossier built on 25°C/60% RH data will not support a zone IVb registration.
What is significant change in a stability study?
For a drug product it means a 5% change in assay from the initial value, any degradation product exceeding its acceptance criterion, failure of appearance, physical attribute or functionality criteria, failure of the pH criterion, or failure of dissolution criteria for 12 dosage units. For a drug substance it means failure to meet specification. If it occurs at the accelerated condition, intermediate testing at 30°C/65% RH becomes necessary.
What is forced degradation and why is it required?
Forced degradation, also called stress testing, deliberately exposes the drug substance to harsh conditions — heat above the accelerated condition, high humidity, acid and base hydrolysis, oxidation, and light. It runs on a single batch, separate from the formal stability study. Its purpose is to identify the degradation products the molecule forms, proving the analytical method can quantify the active ingredient in their presence. That makes the method stability-indicating.
What is the difference between an API retest date and an expiry date?
A finished dosage form carries an expiry date, after which it must not be used or supplied under any circumstances. An API usually carries a retest date instead. When that date is reached the material is sampled and retested against its specification, and if it passes it can go into manufacture with a new retest date assigned. Less stable APIs are given an expiry date instead.
How many batches are needed for stability data in a registration dossier?
Registration normally requires at least three primary batches of both the drug substance and the drug product. For the drug product, at least two should be at pilot scale, with the third permitted to be smaller if justified. All batches must use the same process, specification, and container closure system proposed for marketing. Twelve months of long-term and six months of accelerated data is the usual minimum at submission.
What are bracketing and matrixing in stability testing?
Both are reduced designs permitted by ICH Q1D to cut the number of samples tested. Bracketing tests only the extremes of a variable — lowest and highest strength, smallest and largest container — assuming intermediate combinations behave similarly. Matrixing tests a defined subset at each time point, rotating which combinations are pulled, so all are covered across the study but not at every interval. Initial and final points are always tested in full.
What stability documents should I request from a pharmaceutical supplier?
Ask for the full stability report rather than a summary. It should state batch numbers, manufacturing dates, batch sizes, the storage conditions with tolerances, the container closure system, the analytical methods, and the complete data tables at every time point. Also request the stability-indicating method validation report with forced degradation results, and confirmation of which climatic zone conditions were run and how many months are complete.
Final Thoughts
Stability data is slow to generate and impossible to backdate. That single fact causes most of the delays exporters hit when a market is added late.
Read the tables, not the claim. A shelf life is only as good as the conditions it ran at and the real-time months behind it.
Request a Quotation or Discuss Your Requirements
AksharAvira Pharma supplies APIs, generics, and finished dosage forms to buyers in regulated and semi-regulated markets. To confirm stability conditions, shelf-life documentation, or climatic zone data for a destination, contact our team.